A Legacy of Innovation
Since 1937, Baxter has been responsible for introducing some extraordinary medical breakthroughs to Canadian patients and healthcare professionals, including intravenous medicine, medication delivery devices and the first home-based dialysis system as an alternative to haemodialysis in a hospital or clinic.
- The first commercially manufactured intravenous (IV) solution
- The first commercially built artificial kidney
- The first commercially produced Factor VIII concentrate to treat hemophilia
- The first closed system IV containers
- The first premixed drug solutions
- The first peritoneal dialysis (PD) solutions and delivery systems
- The first automated blood-cell separation system
- The first heat-treated Factor VIII concentrate
- The first Factor VIII concentrate purified by chemical and monoclonal techniques
- The first “needle-less” system for IV therapy
- The first Factor VIII product made without the addition of any human or animal plasma proteins in the manufacturing process
- The first antimicrobial-coated IV connector
- The first out-of-hospital admixture facility in Canada
- The first disease management program for Canadian renal patients
1931 — Baxter International Inc. is founded as the first manufacturer of commercially prepared intravenous (IV) solutions.
1937 — Baxter expanded into Canada as the company’s first international location outside the United States. Seven employees, working out of a rented building in Toronto, produced intravenous solutions in glass bottles.
1940 — Baxter established its first Canadian manufacturing facility. The facility was located in Acton, Ontario.
1957 — Baxter relocates its manufacturing facility from Acton, Ontario, to Alliston, Ontario. The 180,000-square-foot plant, which currently employs more than 400 people, manufactures life-sustaining intravenous (IV), nutritional, peritoneal dialysis and hemodialysis solutions - 99 per cent of which are sold in Canada. Baxter’s Alliston facility is the longest standing parenteral solutions plant in Canada and the only Canadian manufacturer of peritoneal dialysis solutions.
1961 — Baxter stock begins trading on the New York Stock Exchange.
1983 Baxter established its second Canadian manufacturing facility in Sherbrooke, Quebec. The 35,000-square foot facility produced medical sets for the IV administration of medications and solutions.
1986 — Baxter opened Canada’s first out-of-hospital admixture facility. Featuring state-of-the-art quality control processes and clean room technology, Baxter’s Central Intravenous Admixture (CIVA) pharmacy service provides Canadian hospital pharmacists and healthcare professionals with sterile parenteral therapies in a wide array of compounded formulations with extended shelf-life. Baxter’s CIVA Pharmacy Services provides a range of IV therapies encompassing oncology, anti-infectives, analgesics, parenteral nutrition, critical care areas and cardioplegic solutions.
2005 — Baxter’s Sherbrooke facility became the first Canadian manufacturing facility to receive Carbon Neutral Certification, awarded by TreeCanada.
2007 — Baxter’s Alliston manufacturing facility celebrates its 50th anniversary.
2008 — Baxter’s Sherbrooke manufacturing facility celebrates its 25th anniversary.
2011 — Baxter opens new Canadian headquarters in a facility built to Leed Gold green specifications in Mississauga.
2012 — Baxter celebrates 75 years of innovation and leadership in Canadian healthcare.
2015 — Baxter successfully spins off its BioScience business into Baxalta incorporated.
2017 — A new, state-of-the-art admixing facility, Baxter CIVA, opens in Mississauga, Ontario. The new facility expands Baxter’s ability to meet the needs of Canadian hospitals, clinics and other care facilities for ready-to-administer intravenous (IV) admixtures. This includes chemotherapy, high alert medications and anti-infectives, enabling pharmacists to focus on more direct patient care and clinical activities.